Analyst consensus rating

GRI Bio Analyst Rating: none

Direct answer

GRI Bio's consensus rating is none.

2 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $18.50.
Forecast evidence checked November 17, 2026.

Get free GRI Bio email updates.

Bullstory sends one daily email when new analysis or important company news is available.

Verified data

Current price
$1.40
Average price target
$18.50
High price target
$27.00
Low price target
$10.00
Low target gap
+614.3%
Target upside
+1,221.4%
High target gap
+1,828.6%
Target range width
1,214.3%
Consensus rating
none
Analysts
2
Evidence date
November 17, 2026
Valid through
November 24, 2026

Read the frequently asked questions.

What is the analyst consensus rating for GRI Bio?

GRI Bio has a verified none consensus. The same dataset has an average price target of $18.50.

How far are GRI Bio's low and high targets from the recorded price?

The low target implies +614.3%, while the high target implies +1,828.6%.

How many analysts are included in GRI Bio's consensus?

The verified consensus includes 2 analysts.

How is GRI Bio's target upside or downside calculated?

The average target of $18.50 is divided by the recorded price of $1.40, then one is subtracted to produce +1,221.4%. This does not guarantee a future return.

When was GRI Bio's analyst forecast verified?

The data was verified on 2026-11-17. The dataset is valid through 2026-11-24.